Fuller & Thaler Asset Management
CRBP icon

Fuller & Thaler Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Fuller & Thaler Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,998
Closed -$1.47M – 488
2019
Q4 		$1.47M Buy
8,998
+30
+0.3% +$4.43K 0.02% 313
2019
Q3 		$1.31M Hold
8,968
– – 0.02% 324
2019
Q2 		$1.86M Sell
8,968
-50
-0.6% -$10.7K 0.02% 296
2019
Q1 		$1.88M Buy
9,018
+278
+3% +$61.3K 0.02% 288
2018
Q4 		$1.53M Buy
8,740
+27
+0.3% +$5.39K 0.02% 298
2018
Q3 		$1.97M Buy
+8,713
New +$1.41M 0.02% 304

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fuller & Thaler Asset Management's CRBP Position: Q1 2020 in Review

Fuller & Thaler Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2020, closing a stake of 8,998 shares — an estimated $1.47M sold.

Fuller & Thaler Asset Management first reported a position in CRBP in Q3 2018 and held it in 6 quarters. The position peaked at $1.97M in Q3 2018. 111 funds tracked by Wall St. Rank hold CRBP as of Q1 2020.

  • Fuller & Thaler Asset Management reported no remaining Corbus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 8,998 Corbus Pharmaceuticals shares in Q1 2020, an estimated $1.47M.
  • Fuller & Thaler Asset Management first reported a position in Corbus Pharmaceuticals in Q3 2018 and held it in 6 quarters.
  • Fuller & Thaler Asset Management's Corbus Pharmaceuticals position peaked at $1.97M in Q3 2018.
  • 111 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2020.

Based on Fuller & Thaler Asset Management's 13F filing for Q1 2020, filed 6 May 2020.